Christopher G. Bunick, MD, PhD

Angelika Erwin, MD, PhD, joins the podcast to discuss diagnosing and managing EPP and XLP on ABCs in Dermatology.

Hosts discuss the latest data in psoriasis and the case for treating scalp, nail, and genital psoriasis as systemic-eligible disease.

New AD biologic data highlight early systemic treatment, durable itch control, and improved pediatric growth—shifting goals beyond skin clearance.

The topic of precision medicine in dermatology is explored in this segment of Bunick's interview at RAD 2026.

This interview at RAD highlights FDA-approved therapies in the atopic dermatitis treatment armamentarium.

The latest ABCs of Dermatology explored the future potential of amlitelimab in atopic dermatitis and the potential of OX40 ligand-targeted therapy.

Amlitelimab was discussed in the ABCs in Dermatology podcast, with the hosts highlighting atopic dermatitis patient demographics and high disease burden.

Explore OX40/OX40L inhibition in atopic dermatitis: phase 3 amlitelimab efficacy, safety signals, and what upstream immune control could mean.

This Q&A interview highlights emerging therapies for atopic dermatitis, featuring Christopher G. Bunick, MD, PhD of Yale Medicine.

Christopher Bunick, MD, PhD, and colleagues conducted a review bispecific and trispecific antibodies in atopic dermatitis.

Late-breaking AAD 2026 trials spotlight PsA weight-loss combo, twice-yearly IL-13 dosing for atopic dermatitis, and a rapid oral TYK2 pill for psoriasis.

Chris Bunick, MD, PhD, and Lindsay Ackerman, MD, preview the 2026 American Academy of Dermatology Annual Meeting.

Hosts reveal how research, mentors, and clinic rotations spark a passion for skin disease and what makes dermatology unique.

A clip from an episode of ABCs in Dermatology showcases perspective into the personal lives of hosts Chris Bunick, MD, PhD, and Lindsay Ackerman, MD.

Experts unpack biologics, molecular know-how, and patient trust—plus key previews for the upcoming AAD Annual Meeting.

Panelists discuss the questions below in this video. Looking ahead, what are your hopes for the future of psoriasis care with targeted oral therapies like TYK2 inhibitors, and what final reflections do you have on their emerging role in clinical practice?

Panelists discuss the questions below in this video. What do we know about the therapeutic potential of TYK2 inhibition in psoriatic arthritis?

Panelists discuss the questions below in this video. ESK-001, another highly selective TYK2 inhibitor, has advanced into phase 3 trials in plaque psoriasis. How does its mechanism of action and emerging phase 2 data compare with deucravacitinib and zasocitinib, and what features might distinguish it within the TYK2 inhibitor class?

Panelists discuss the questions below in this video. How do you see emerging TYK2 inhibitors, such as zasocitinib and ESK-001, fitting into the psoriasis treatment landscape, if approved? Building on IMMpulse findings that earlier biologic use in moderate psoriasis can improve outcomes, what opportunities do you see for TYK2 inhibitors to be used earlier in appropriate patients?

What are your impressions of the Phase 2b data of zasocitinib in psoriasis, particularly in terms of Psoriasis Area and Severity Index (PASI) responses, dose-dependent effects, and tolerability? How do you see these results influencing your real-world patient selection?

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

Next-generation TIC-2 inhibitors show remarkable selectivity, enhancing efficacy while minimizing side effects, offering insights into immune system safety.

Explore the distinct role of TIC-2 in psoriasis and how selective inhibition offers targeted treatment advantages over traditional JAK inhibitors.

Experts discuss the future of psoriasis treatment, highlighting the potential of oral therapies to enhance patient adherence and quality of life.

Explore the complexities of psoriasis treatment, including advanced therapies, mechanisms of action, and the potential of molecular testing for personalized care.

Panelists examine how these emerging therapies compare with existing options and consider what their advances mean for clinicians and patients in everyday practice.

Panelists examine how these emerging therapies compare with existing options and consider what their advances mean for clinicians and patients in everyday practice.

A pair of leading subject matter experts discuss the current landscape of atopic dermatitis, including unmet needs, and the role of IL-13 inhibition in the management.

In this set of interviews, 6 leaders in the field of dermatology highlight their experiences at the 2025 EADV Congress.

A pair of leading subject matter experts discuss the current landscape of atopic dermatitis, including unmet needs, and the role of IL-13 inhibition in the management.